КЛІНІЧНИЙ ВИПАДОК ПЕРВИННОЇ ОСТЕОСАРКОМИ ЯЄЧНИКІВ
We describe an extremely rare clinical case of primary ovarian osteosarcoma (OS) in a 70-year-old woman, along with the diagnostic criteria for this condition. The patient underwent chemotherapy and has been under observation for 27 months. Currently, tumor progression with metastatic lesions of the...
Збережено в:
| Дата: | 2026 |
|---|---|
| Автори: | , , , |
| Формат: | Стаття |
| Мова: | Англійська |
| Опубліковано: |
PH Akademperiodyka
2026
|
| Теми: | |
| Онлайн доступ: | https://exp-oncology.com.ua/index.php/Exp/article/view/618 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Experimental Oncology |
| Завантажити файл: |  |
Репозитарії
Experimental Oncology| _version_ | 1868113233329520640 |
|---|---|
| author | Manzhura, O. Zakhartseva, L. Maystrenko, Ye. Kravchuk, O. |
| author_facet | Manzhura, O. Zakhartseva, L. Maystrenko, Ye. Kravchuk, O. |
| author_institution_txt_mv | [
{
"author": "O. Manzhura",
"institution": "Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine"
},
{
"author": "L. Zakhartseva",
"institution": "Kyiv City Clinical Oncology Center, Kyiv, Ukraine"
},
{
"author": "Ye. Maystrenko",
"institution": "Kyiv City Clinical Oncology Center, Kyiv, Ukraine"
},
{
"author": "O. Kravchuk",
"institution": "Kyiv City Clinical Oncology Center, Kyiv, Ukraine"
}
] |
| author_sort | Manzhura, O. |
| baseUrl_str | https://exp-oncology.com.ua/index.php/Exp/oai |
| collection | OJS |
| datestamp_date | 2026-06-15T10:40:10Z |
| description | We describe an extremely rare clinical case of primary ovarian osteosarcoma (OS) in a 70-year-old woman, along with the diagnostic criteria for this condition. The patient underwent chemotherapy and has been under observation for 27 months. Currently, tumor progression with metastatic lesions of the peritoneum is observed. This case highlights the importance of further studies of primary ovarian OS. Ovarian OS is not included in the 2022 WhO classification of genital tumors, but such cases occur; their diagnosis is difficult, and there is no consensus on the treatment. Accumulat- ing data on the structural features of these tumors and their response to treatment will help improve the understanding of their treatment. |
| doi_str_mv | 10.15407/exp-oncology.2026.01.051 |
| first_indexed | 2026-06-15T01:00:21Z |
| format | Article |
| fulltext |
51
CASE REPORTS
C i t a t i o n: Manzhura O, Zakhartseva L, Maystrenko Ye, Kravchuk O. Clinical case of primary ovarian osteosarcoma.
Exp Oncol. 2026; 48(1): 51-58. https://doi.org/10.15407/exp-oncology.2026.01.051
© PH “Akademperiodyka” of the NAS of Ukraine, 2026. This is an open access article under the CC BY-NC-ND license
(https://creativecommons.org/licenses/by-nc-nd/4.0/)
Ovarian tumors are the eighth most common cancer
among women worldwide, with the highest inci-
dence rates observed in Central and Eastern Europe,
North America, and Southeast Asia. Most of these
tumors are high-grade carcinomas [1]. Stromal tu-
mors are less common and arise primarily from the
stromal tissue of the gonadal sex cords. Teratomas
with a malignant component are even less common
(about 2% of all tumors), and 80% of them contain
a dermoid component or, less commonly, adenocar-
cinoma, melanoma, or another malignancy. Osteo-
sarcoma (OS) may arise from teratoma, malignant
mixed neuroectodermal tumor, primitive ovarian
stromal cells, or metaplastic stromal cells [2]. In
most cases, teratomas contain multiple components,
which complicate correct diagnosis. Only 8% of ma-
lignant teratomas contain elements of sarcoma, and
cases of the tumor consisting exclusively of a sarco-
matous component are extremely rare. To confirm
the diagnosis of primary ovarian OS, it is necessary
to exclude soft tissue or bone tumors.
OS is more common in men in the second de-
cade of life, especially during the pubertal bone
growth spurt. The most common sites are the distal
femoral metaphysis and the proximal tibial me-
taphysis, with 60% of cases occurring in individuals
under 25 years of age [3]. OS is extremely rare in
the elderly and occurs against the background of
chronic osteomyelitis or Paget’s disease. Pain is the
main clinical symptom. Sometimes, OS can occur
in soft tissues. Extraskeletal OS, according to the
WHO classification, refers to soft tissue sarcomas.
https://doi.org/10.15407/exp-oncology.2026.01.051
O. Manzhura 1, 2, L. Zakhartseva 2, 3,
Ye. Maystrenko 2, O. Kravchuk 2, *
1 Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
2 Kyiv City Clinical Oncology Center, Kyiv, Ukraine
3 Bogomolets National Medical University, Kyiv, Ukraine
* Correspondence: E-mail: oksanapad95@gmail.com
Clinical Case of Primary
Ovarian Osteosarcoma
We describe an extremely rare clinical case of primary ovarian osteosarcoma (OS) in a 70-year-old woman, along with
the diagnostic criteria for this condition. The patient underwent chemotherapy and has been under observation for
27 months. Currently, tumor progression with metastatic lesions of the peritoneum is observed. This case highlights
the importance of further studies of primary ovarian OS. Ovarian OS is not included in the 2022 WHO classification of
genital tumors, but such cases occur; their diagnosis is difficult, and there is no consensus on the treatment. Accumulat-
ing data on the structural features of these tumors and their response to treatment will help improve the understanding
of their treatment.
Keywords: ovarian cancer, osteosarcoma of the ovary, osteosarcoma, teratoma.
52 ISSN 1812-9269. Experimental Oncology 48 (1). 2026
O. Manzhura, L. Zakhartseva, Ye. Maystrenko, O. Kravchuk
However, soft tissue morphology and bone osteo-
genesis have common features and contain varying
amounts of neoplastic bone, cartilage, and/or fibro-
blastic components; based on the predominant ma-
trix, they are divided into different types. Approx-
imately 80%—90% of OS are represented by “clas-
sic” osteoblastic types, classified by WHO as OS
without further specification (ICD-O code 9180/3)
[4]. Less common types include chondroblastic OS
(ICD-O code 9181/3) and fibroblastic OS (ICD-O
code 9182/3). Telangiectatic OS (ICD-O code
9183/3) and small cell OS (ICD-O code 9185/3)
share similar biological features. Superficial osteo-
genic paraosseous OS is low-grade, and periosteal
OS is moderately differentiated. However, the clas-
sic OS is always high-grade [5]. Since our case de-
scribes a classic osteoblastic ovarian OS, we will fo-
cus on this type of malignancy.
As follows from the previously mentioned classi-
fication, OS histology is polymorphic, but it is always
possible to identify signs of tumor bone formation,
which is predominant in the osteoblastic type. Neo-
plastic bone can be represented by small amorphous
fragments or a fine network of osteoid, sometimes
resembling bone trabeculae. Areas of malformed
pleomorphic cells resembling pleomorphic sarcoma
may be present, as well as atypical cartilage and fi-
brous tissue. The mitotic activity is usually high, of-
ten with an abundance of atypical mitotic figures,
which is useful in the differential diagnosis with be-
nign tumors. Despite the diverse morphology, neo-
plastic bone formations are important for diagnosis.
There is no required threshold value for the mini-
mum number of neoplastic bone formations; any
number is sufficient for diagnosis. Bone matrix, in-
cluding tumor matrix, appears eosinophilic in hema-
toxylin-eosin-stained sections if not mineralized and
basophilic if mineralized. The differentiation be-
tween non-mineralized matrix (osteoid) and other
eosinophilic extracellular substances, such as colla-
gen or fibrin, can be challenging. Immunohisto-
chemistry (IHC) using SATB2 antibodies to indicate
osteoblastic differentiation can facilitate the diagno-
sis. SATB2 belongs to the matrix attachment re-
gion-binding transcription factor family. This mark-
er has a positive nuclear expression in all OS, both
skeletal and extraskeletal. However, it is not specific
as it is often expressed in osteoblastoma, osteoid os-
teoma, fibrous dysplasia, giant cell tumor, and co
lorectal adenocarcinoma. Therefore, a histological
diagnosis is made based on a combination of various
data, namely the morphological structure in diffe
rent tumor areas and IHC results using a panel of
antibodies, including markers characteristic not only
of OS but also helping to exclude carcinoma ele-
ments. Typically, in OS, in addition to SATB2, osteo-
calcin (BGLAP), osteonectin (SPARC), osteoprote-
gerin (TNFRSF11B), RUNX2, S100, actins, and
CD99 are expressed [4, 6].
Diagnosis of primary ovarian OS before surgery
is unlikely, as calcifications on radiographs are not
specific to it. Calcifications were noted in two-
thirds of the teratomas in the series described by
Siegel et al. [7]. Of the 80 gonadal blastomas repor
ted in two series, 7 cases had calcifications that
could be visualized on abdominal radiographs. Fi-
nally, in a Mayo Clinic series, extensive calcifica-
tion was observed in 4% of 263 ovarian fibroids [8].
All cases of primary OS described in the litera-
ture were diagnosed based on surgical or patholo
gical examination data.
In our 40-year-long practice (annually, Kyiv City
Oncological Center performs an average of 180
surgeries for ovarian tumors, 90 of which are ma-
lignant), the first case of primary ovarian OS has
been diagnosed.
Case presentation
The patient was a 70-year-old woman with a his-
tory of one birth and no abortions; by the time of
treatment (in Kyiv City Oncological Center from
May 2023), she had been in menopause for 25
years. The patient presented with complaints of ab-
dominal bloating and lower abdominal pain for the
past 6 months and had not visited a gynecologist
for the past 7 years. There was no family history of
cancer. The patient underwent a comprehensive ex-
amination, including CT of three zones with con-
trast, esophagogastroduodenoscopy, and tumor
marker analysis.
CT revealed a complex cystic mass with contrast
enhancement in the left ovary projection, sized
14 × 10 cm, with lobular, clearly defined contours,
compressing the uterine body, without intestine
and large vessels invasion (Fig. 1).
No signs of secondary involvement were seen:
the lymph nodes were not enlarged, and no bone
lesions were found, which indicates primary ova
rian malignancy.
ISSN 1812-9269. Experimental Oncology 48 (1). 2026 53
Clinical Case of Primary Ovarian Osteosarcoma
Tumor markers: CA-125 — 6.76 U/mL (normal
range <35), HE4 — 138.13 pmol/mL (normal range
<70), ROMA index — 17.3%.
Preliminary diagnosis: Neoplasm of the left ova-
ry, suspected of being malignant. Surgical treat-
ment was performed: visceral separation, abdom-
inal hysterectomy with bilateral tubo-oophorec-
tomy (type II), and omentectomy. During the
revision, damage to the tumor capsule of the left
ovary was found. The right ovary was enlarged to
4.5 cm; the surface was smooth. The uterine body
was of normal size; adjacent organs were not
changed. No signs of dissemination were detected.
The omentum and liver showed no abnormalities.
No residual tumor was found.
Gross pathology: The body of the uterus was not
enlarged, the endometrium was atrophic, and the
cervix and cervical canal were normal. The left ova-
ry presented a complex cystic mass, measuring 14 ×
×10 cm; on section, the solid component occupied
2/3 of the area and had a dense, bony structure. The
cystic component was represented by dark hemor-
rhagic contents, the outer capsule was smooth, and
multiple papillary structures were visible on the in-
ner surface. The Fallopian tubes were normal. The
right ovary was enlarged to 4.5 cm, the surface was
smooth, and on the section, it appeared intact.
Histopathological description: A tumor in the left
ovary was characterized by proliferation of atypical
polygonal and spindle-shaped cells and the forma-
tion of neoplastic osteoid and numerous osteo-
clast-like giant cells (Fig. 2, a, b). The tumor cells
showed high-grade nuclear atypia and significant
mitotic activity. The microscopic fragments of the
cyst epithelial lining, represented by monomorphic
single-layer epithelium, were found in the capsule
of the tumor node. The right ovary, Fallopian tubes,
endometrium, cervix, and omentum showed no
sign of tumor.
IHC analysis: Cytokeratin pan (AE1 and AE3) —
negative reaction in tumor cells (Fig. 3, a), positive
reaction in a small number of cells of single-layered
Fig. 2. OS histopathology: a — a homogeneous osteoid mass is seen in the tumor, with osteoclasts of different sizes
(yellow arrow) and polymorphic nuclei on the periphery (black arrow), along with a loose fibrous matrix. H&E, ×100;
b — typical osteoid (yellow arrow) against the background of osteoblast proliferation, with isolated osteoclasts (black
arrow). H&E, ×200
Fig. 1. Chest, abdominal, and pelvic CT images show a complex cystic mass in the pelvic projection
54 ISSN 1812-9269. Experimental Oncology 48 (1). 2026
O. Manzhura, L. Zakhartseva, Ye. Maystrenko, O. Kravchuk
course, cisplatin 20 mg/m² — 160 mg per course).
According to the NCCN recommendations, cispla-
tin/ifosfamide are used to treat ovarian carcinosar-
comas, including OS. At the clinical tumor council,
we decided, based on the available research, to con-
duct treatment according to the IP regimen [9—13].
After completion of the specialized treatment,
the patient felt well. A CT scan of three zones and
an MRI of the pelvis with contrast revealed no sign
of disease progression.
A year later, the disease relapsed. CT with con-
trast revealed multiple nodular formations in the
parietal peritoneum and pelvic cavity, in contact
with the walls of the sigmoid colon and bladder,
and the ascites. In addition, the levels of tumor
markers increased: CA-125 — 30.6 U/mL, HE4 —
Fig. 4. Immunostaining for SATB2: a — positive reac-
tion in tumor cells nuclei (yellow arrow), ×200. CD68;
b — positive reaction in large cells (osteoclasts) (black ar-
row), ×200. Ki-67; c — positive reaction in proliferating
cells (black arrow), ×200
cyst epithelium, found in the tumor capsule
(Fig. 3, b); CD 68 (KP1) — positive reaction in osteo-
clast-like giant cells (less than 5%); Ki‑67 (MIB‑1) —
45% in tumor cells; vimentin (Vim3B4) — positive
reaction in tumor cells; SATB2 (EP281) — positive
reaction in tumor cells (Fig. 4); cytokeratin 7 (OV‑TL
12/30) — positive reaction in less than 5% of sin-
gle-layered epithelium area.
Based on histopathological and IHC examina-
tion data, the OS of the left ovary was diagnosed.
The postoperative period was uneventful, and
the patient was discharged in satisfactory condition
on the eighth day after the surgery.
One month after the surgery, chemotherapy was
started, four courses were administered according to
the IP scheme (ifosfamide 1.5 g/m² — 12 g per
Fig. 3. Immunostaining for CK-Pan A: a — negative reaction in atypical tumor cells, which argues against the presence
of carcinoma, ×200; b — CK-Pan, positive reaction in the cyst epithelial lining, detected within the tumor capsule, ×200
ISSN 1812-9269. Experimental Oncology 48 (1). 2026 55
Clinical Case of Primary Ovarian Osteosarcoma
534.9 pmol/L, and the ROMA index — 72.06%.
Considering the results and the 12-month re-
lapse-free period, we believe that the treatment was
appropriate for the patient and deserved attention.
Discussion
OS of the ovary is very rare, with only a few cases
documented in the literature. This highlights the im-
portance of each case for understanding the origin
and clinical behavior of this tumor. These rare cases
provide a critical perspective and may help identify
risk factors, optimize diagnostics, and develop effec-
tive treatment strategies. Further documentation
and study of such cases are necessary to improve
knowledge in this area and optimize patient care.
Our patient was alive for 27 months after the
surgery, although she had multiple metastases in
the abdominal cavity.
In 2006, Fadare et al. [6] described their observa-
tion of ovarian OS and reviewed all previously report-
ed cases. A total of 13 patients: 6 primary cases of OS
(mean age of patients 52.6 years), 5 OS in teratoma
(mean age 52 years), and 2 cases of OS metastases to
the humerus and maxilla (mean age 37.5 years) were
described. Most patients had FIGO stage 3 or 4, with
survival rates of 4.8 and 3.5 months, respectively.
Hines et al. [5] described a case of primary ovar-
ian OS in a 53-year-old woman who had 5 success-
ful deliveries and survived 5 months after surgery.
In a younger patient (aged 43), the primary ovarian
OS was large and spread to the uterus, small intes-
tine, and bladder. The patient survived 18 days af-
ter surgery and died of intestinal obstruction.
Yesmin et al. [9] reported a case of primary ovar-
ian OS based on autopsy findings in a 50-year-old
woman. No evidence of occult teratoma was ob-
served, leaving the pathogenesis of this case unclear.
A brief review of the literature on ovarian OS is
presented in Table (see the list of corresponding
references in [6]).
In all reported cases, the patients were 24—
80 years old, the tumors ranged in size from 8 to
22 cm, and survival time ranged from 1 to
16 months, with two patients remaining asymp-
tomatic for 16 months and 3 years.
Summary of the clinicopathological features, treatment, and outcomes
of primary ovarian OS cases presented in the literature
Original study Patient age, years Tumor size, cm FIGO stage Treatment Follow-up
Azoury and Woodruff, 1971 41 21 III Surgery DOD
5 months
Shakfeh and Woodruff, 1987 24 NS IV Surgery DOD
5 months
Hirakawa et al., 1988 47 17 III Surgery/Chemotherapy DOD
8 months
Hines et al., 1990 53 2 I Surgery/Chemotherapy NED
Sakata et al., 1991 75 10 IV Surgery DOD
4 months
Stowe and Watt, 1952 67 15 III Surgery DOD
5 months
Burgess and Shutter, 1954 47 19 I Surgery NS
Ngwalle et al., 1990 52 3,1 I Surgery/Chemotherapy RFT
16 months
Ajithkumar et al., 1999 80 10 III Surgery/Chemotherapy DOD
2 months
Aygun et al., 2003 14 22 III Surgery/Chemotherapy RFT
7 months
Yeasmin et al., 2009 50 8 IV Chemotherapy DOD
1 months
Present case 70 14 I Surgery/Chemotherapy RFT
12 months
Notes: DOD — death after diagnosis; NED — no evidence of disease; RFT — relapse-free time; NS — not stated.
56 ISSN 1812-9269. Experimental Oncology 48 (1). 2026
O. Manzhura, L. Zakhartseva, Ye. Maystrenko, O. Kravchuk
Our patient was alive for 27 months, despite the
development of peritoneal metastases 12 months
after the surgery. As in all the other cases, the diag-
nosis of OS was made postoperatively, although
calcifications were visualized on CT; however, this
sign is not specific for this tumor. The intraopera-
tive express histological examination was impossi-
ble due to the high tissue density and extensive foci
of bone tissue requiring decalcification. Microscop-
ic examination of sections stained with hematoxy-
lin and eosin revealed pure ovarian OS. Conside
ring the discrepancies with cases described in the
literature, it was decided to verify the diagnosis us-
ing IHC, which would confirm the absence of oth-
er stromal and epithelial components (CK–) in the
tumor, and the presence of osteogenic differentia-
tion (SATB2+). OS usually does not cause difficul-
ties in morphological diagnosis due to its typical
localization in bones and soft tissues. In our case,
during the examination of the tumor capsule, a mi-
croscopic fragment of the cyst epithelial lining was
detected, which is an extremely valuable finding for
the ovarian OS histogenesis understanding, con-
firming its teratoma origin.
Considering that primary ovarian OS is an ex-
tremely rare disease, there is no unified treatment
protocol. Researchers agree that survival rates im-
prove after radical surgical treatment, but at a late
stage, this may not be possible. There is no consen-
sus regarding chemotherapy, as it does not always
provide encouraging results.
Before 1972, many studies of adjuvant chemother-
apy using high doses of methotrexate in combina-
tion with leucovorin, doxorubicin, cisplatin, cyclo-
phosphamide, dactinomycin, and vincristine had
been conducted, but the results were disappointing.
Among all drugs, doxorubicin showed the best re-
sponse [14, 15]. Doxorubicin, high-dose methotrex-
ate, and cisplatin are the most effective agents for OS
treatment [15, 16]. Many combinations are current-
ly being studied, including doxorubicin–cisplatin,
vincristine–methotrexate, and doxorubicin–metho-
trexate. Thus, Hines et al. [5] have described a course
of adjuvant chemotherapy in a patient, consisting of
doxorubicin (60 mg/m²) and cisplatin (75 mg/m²)
for eight cycles, followed by a remission for more
than 5 months. Vyas et al. [8] have examined data
from 11 cases of ovarian OS, treated by adjuvant ra-
diotherapy, multimodal chemotherapy, and surgical
intervention. 8 of 11 patients died of progressive dis-
ease within 2—8 months, and one patient had a local
recurrence after 7 months. Only two patients were
long-term survivors, and both received combination
chemotherapy with doxorubicin and cisplatin after
complete resection. The best survival rates were ob-
served in cases where complete resection of the pri-
mary tumor was performed, whereas patients with
incomplete resection experienced early recurrence
and died within a few months.
Based on the evaluation of the data presented in
the literature and our observation, we can conclude
that OS is an extremely rare, highly malignant ovar-
ian tumor, probably originating from a teratoma. Ex-
clusion of bone or soft tissue tumors is important in
primary OS diagnosis. Preoperative diagnosis is ex-
tremely confusing. Although CT scanning visualizes
a heterogeneous mass with areas of suspected ossifi-
cation or calcification, this is not sufficient to suspect
OS, since these features may also be present in other
tumors. Most OS cases are represented by the osteo-
blastic type; therefore, malignant osteogenesis is
common; chondroblastic and fibroblastic compo-
nents are much less common. The absence of carci-
noma and other types of sarcomas allows us to ex-
clude multicomponent malignant teratoma. OS cli
nical course is very aggressive, with extensive
metastases. In our case, the patient showed signs of
relapse 12 months after the surgery. The observation
has been ongoing for 23 months; the patient was di-
agnosed with multiple metastases in the abdominal
cavity. Therefore, radical surgical treatment with ad-
juvant chemotherapy improves survival rates.
Ethical approval
and consent to participate
We publish this case considering the patient’s signed
informed voluntary consent according to the Dec-
laration of Helsinki. The Ethics Committee of the
Kyiv City Clinical Oncology Center reviewed our
application and the patient’s informed consent, and
no permission was required. Approval number
061/17-1267 from 12/06/2024.
Funding
This research received no external funding.
Conflict of interest
The authors declare no conflict of interest.
ISSN 1812-9269. Experimental Oncology 48 (1). 2026 57
Clinical Case of Primary Ovarian Osteosarcoma
REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mor-
tality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. https://doi.org/10.3322/
caac.21834
2. Lacoste C, Cormier B, Marret H, et al. Primary osteosarcoma of the ovary. Gynecol Obstet Fertil. 2015;43(7-8):555-
556. https://doi.org/10.1016/j.gyobfe.2015.06.001
3. Hauben EI, Weeden S, Pringle J, et al. Does the histological subtype of high-grade central osteosarcoma influ-
ence the response to treatment with chemotherapy, and does it affect overall survival? A study on 570 patients of
two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer. 2002;38(9):1218-1225. https://doi.
org/10.1016/s0959-8049(02)00037-0
4. Machado I, Navarro S, Picci P, et al. The utility of SATB2 immunohistochemical expression in distinguishing be-
tween osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Pathol Res Pract. 2016;212(9):811-816. https://doi.org/10.1016/j.prp.2016.06.012
5. Hines JF, Compton DM, Stacy CC, et al. Pure primary osteosarcoma of the ovary presenting as an extensively
calcified adnexal mass: a case report and review of the literature. Gynecol Oncol. 1990;39(3):259-263. https://doi.
org/10.1016/0090-8258(90)90248-j
6. Fadare O, Bossuyt V, Martel M, et al. Primary osteosarcoma of the ovary: a case report and literature review. Int J
Gynecol Pathol. 2007;26(1):21-25. https://doi.org/10.1097/01.pgp.0000225840.36750.a2
7. Siegel MJ, McAlister WH, Shackelford GD. Radiographic findings in ovarian teratomas in children. AJR Am J
Roentgenol. 1978;131(4):613-615. https://doi.org/10.2214/ajr.131.4.613
8. Vyas V, Rammah AM, Ashebu SD, et al. A case report of primary osteosarcoma of the ovary. Int J Gynecol Cancer.
2006;16 Suppl 1:349-52. https://doi.org/10.1111/j.1525-1438.2006.00485.x
9. Yeasmin S, Nakayama K, Ishibashi M, et al. Primary osteosarcoma of the ovary. Int J Clin Oncol. 2009;14(2):163-
166. https://doi.org/10.1007/s10147-008-0807-x
10. National Comprehensive Cancer Network. Bone cancer (Version 1.2025) [Internet]. Plymouth Meeting (PA):
NCCN; 2024 Aug 20 [cited 2024 Aug 29]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/
bone.pdf
11. Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clini-
cal Practice Guideline for diagnosis, treatment, and follow-up. Ann Oncol. 2021;32(12):1520-1536. https://doi.
org/10.1016/j.annonc.2021.08.1995
12. Valery PC, Laversanne M, Bray F. Bone cancer incidence by morphological subtype: a global assessment. Cancer
Causes Control. 2015;26(8):1127-1139. https://doi.org/10.1007/s10552-015-0607-3
13. Bramwell VH, Steward WP, Nooij M, et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant
fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. J Clin Oncol. 1999;17(10):3260-3267.
https://doi.org/10.1200/JCO.1999.17.10.3260
14. Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemo-
therapy. J Cancer Res Clin Oncol. 1983;106(Suppl):55-67. https://doi.org/10.1007/BF00625054
15. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for non-metastatic osteosarcoma of
the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin
and doxorubicin. Cancer. 1993;72(11):3227-3238. https://doi.org/10.1002/1097-0142(19931201)72:11<3227::aid-
cncr2820721116>3.0.co;2-c
16. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours [Internet]. Lyon (France): Interna-
tional Agency for Research on Cancer; 2020 [cited 2024 Aug 29]. (WHO classification of tumours series, 5th ed.;
vol. 3). Available from: https://publications.iarc.fr/588
Submitted: November 09, 2025
58 ISSN 1812-9269. Experimental Oncology 48 (1). 2026
O. Manzhura, L. Zakhartseva, Ye. Maystrenko, O. Kravchuk
О. Манжура 1, 2, Л. Захарцева 2, 3,
Є. Майстренко 2, О. Кравчук 2
1 Національний університет охорони здоров’я України
імені П.Л. Шупика, Київ, Україна
2 КНП «Київський міський клінічний онкологічний центр»,
Київ, Україна
3 Національний медичний університет
імені О.О. Богомольця, Київ, Україна
КЛІНІЧНИЙ ВИПАДОК ПЕРВИННОЇ
ОСТЕОСАРКОМИ ЯЄЧНИКІВ
Ми описуємо надзвичайно рідкісний клінічний випадок первинної остеосаркоми (ОС) яєчників у 70-річної
жінки, а також діагностичні критерії цього стану. Унікальність цього захворювання та його агресивність, діа-
гностичні помилки в періопераційному періоді роблять цей випадок гідним до представлення. ОС яєчників
не включено до класифікації пухлин статевих органів ВООЗ 2022 року, але такі випадки трапляються, їх діа-
гностика складна, і єдина думка щодо лікування відсутня. Накопичення даних про структурні особливості цих
пухлин та їхню реакцію на лікування допоможе покращити результати лікування. Пацієнтка пройшла хіміо-
терапію та перебуває під спостереженням впродовж 27 місяців. Наразі спостерігається прогресування пухли-
ни з метастатичним ураженням очеревини. Цей випадок підкреслює важливість первинного дослідження ОС
яєчників, яке потребує подальшого вивчення.
Ключові слова: рак яєчників, остеосаркома яєчника, остеосаркома, тератома.
|
| id | oai:ojs2.ex.aqua-time.com.ua:article-618 |
| institution | Experimental Oncology |
| keywords_txt_mv | keywords |
| language | English |
| last_indexed | 2026-06-16T01:00:10Z |
| publishDate | 2026 |
| publisher | PH Akademperiodyka |
| record_format | ojs |
| resource_txt_mv | exp-oncologycomua/10/68e77f6e3f2a06c8666ee7eeecc63610.pdf |
| spelling | oai:ojs2.ex.aqua-time.com.ua:article-6182026-06-15T10:40:10Z Clinical Case of Primary Ovarian Osteosarcoma КЛІНІЧНИЙ ВИПАДОК ПЕРВИННОЇ ОСТЕОСАРКОМИ ЯЄЧНИКІВ Manzhura, O. Zakhartseva, L. Maystrenko, Ye. Kravchuk, O. рак яєчників, остеосаркома яєчника, остеосаркома, тератома ovarian cancer, osteosarcoma of the ovary, osteosarcoma, teratoma We describe an extremely rare clinical case of primary ovarian osteosarcoma (OS) in a 70-year-old woman, along with the diagnostic criteria for this condition. The patient underwent chemotherapy and has been under observation for 27 months. Currently, tumor progression with metastatic lesions of the peritoneum is observed. This case highlights the importance of further studies of primary ovarian OS. Ovarian OS is not included in the 2022 WhO classification of genital tumors, but such cases occur; their diagnosis is difficult, and there is no consensus on the treatment. Accumulat- ing data on the structural features of these tumors and their response to treatment will help improve the understanding of their treatment. Ми описуємо надзвичайно рідкісний клінічний випадок первинної остеосаркоми (ОС) яєчників у 70-річної жінки, а також діагностичні критерії цього стану. Унікальність цього захворювання та його агресивність, діа- гностичні помилки в періопераційному періоді роблять цей випадок гідним до представлення. ОС яєчників не включено до класифікації пухлин статевих органів ВООЗ 2022 року, але такі випадки трапляються, їх діа- гностика складна, і єдина думка щодо лікування відсутня. Накопичення даних про структурні особливості цих пухлин та їхню реакцію на лікування допоможе покращити результати лікування. Пацієнтка пройшла хіміо- терапію та перебуває під спостереженням впродовж 27 місяців. Наразі спостерігається прогресування пухли- ни з метастатичним ураженням очеревини. Цей випадок підкреслює важливість первинного дослідження ОС яєчників, яке потребує подальшого вивчення. PH Akademperiodyka 2026-06-14 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/618 10.15407/exp-oncology.2026.01.051 Experimental Oncology; Vol. 48 No. 1 (2026): Experimental Oncology; 51-58 Експериментальна онкологія; Том 48 № 1 (2026): Експериментальна онкологія; 51-58 2312-8852 1812-9269 10.15407/exp-oncology.2026.01 en https://exp-oncology.com.ua/index.php/Exp/article/view/618/463 Copyright (c) 2026 Experimental Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| spellingShingle | рак яєчників остеосаркома яєчника остеосаркома тератома Manzhura, O. Zakhartseva, L. Maystrenko, Ye. Kravchuk, O. КЛІНІЧНИЙ ВИПАДОК ПЕРВИННОЇ ОСТЕОСАРКОМИ ЯЄЧНИКІВ |
| title | КЛІНІЧНИЙ ВИПАДОК ПЕРВИННОЇ ОСТЕОСАРКОМИ ЯЄЧНИКІВ |
| title_alt | Clinical Case of Primary Ovarian Osteosarcoma |
| title_full | КЛІНІЧНИЙ ВИПАДОК ПЕРВИННОЇ ОСТЕОСАРКОМИ ЯЄЧНИКІВ |
| title_fullStr | КЛІНІЧНИЙ ВИПАДОК ПЕРВИННОЇ ОСТЕОСАРКОМИ ЯЄЧНИКІВ |
| title_full_unstemmed | КЛІНІЧНИЙ ВИПАДОК ПЕРВИННОЇ ОСТЕОСАРКОМИ ЯЄЧНИКІВ |
| title_short | КЛІНІЧНИЙ ВИПАДОК ПЕРВИННОЇ ОСТЕОСАРКОМИ ЯЄЧНИКІВ |
| title_sort | клінічний випадок первинної остеосаркоми яєчників |
| topic | рак яєчників остеосаркома яєчника остеосаркома тератома |
| topic_facet | рак яєчників остеосаркома яєчника остеосаркома тератома ovarian cancer osteosarcoma of the ovary osteosarcoma teratoma |
| url | https://exp-oncology.com.ua/index.php/Exp/article/view/618 |
| work_keys_str_mv | AT manzhurao clinicalcaseofprimaryovarianosteosarcoma AT zakhartseval clinicalcaseofprimaryovarianosteosarcoma AT maystrenkoye clinicalcaseofprimaryovarianosteosarcoma AT kravchuko clinicalcaseofprimaryovarianosteosarcoma AT manzhurao klíníčnijvipadokpervinnoíosteosarkomiâêčnikív AT zakhartseval klíníčnijvipadokpervinnoíosteosarkomiâêčnikív AT maystrenkoye klíníčnijvipadokpervinnoíosteosarkomiâêčnikív AT kravchuko klíníčnijvipadokpervinnoíosteosarkomiâêčnikív |